Temperature-sensitive ovarian carcinoma cell line (OvBH-1)

Japanese Journal of Cancer Research

Volumn 93, Issue 9, 2002, Pages 976-985

  Bar, Julia K ^a   Haroziska, Antonina ^a   Kartarius, Sabine ^b   Montenarh, Mathias ^b   Wyrodek, Ewa ^a   Parkitna, Jan M Rodriguez ^c   Kochman, Marian ^c   Ozyhar, Andrzej ^c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b SAARLAND UNIVERSITY   (Germany)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Cell cycle arrest; Cell line; Ovarian cancer; p53; Temperature sensitivity

Indexed keywords

ADENINE; GUANINE; LYSINE; MONOCLONAL ANTIBODY; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SERINE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ACETYLATION; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BIOCHEMISTRY; CANCER CELL CULTURE; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL GROWTH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC CODE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; ROOM TEMPERATURE; SIGNAL TRANSDUCTION; TEMPERATURE; TEMPERATURE SENSITIVITY; ADENOCARCINOMA; CELL CULTURE; CHEMISTRY; GENETICS; MUTATION; OVARY TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, CLEAR CELL; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENES, P53; HUMANS; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TEMPERATURE; TUMOR CELLS, CULTURED;

EID: 0036747412     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb02473.x     Document Type: Article

References (65)

1. Möbus, V., Gerharz, C. D., Press, U., Moll, R., Beck, T., Mellin, W., Pollow, K., Knapstein, P. G. and Kreienberg, R. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int. J. Cancer, 52, 76-84 (1992).
2. Yaginuma, Y. and Westphal, H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res., 52, 4196-4199 (1992).
3. Hirte, H. W., Kaiser, J. S. and Bacchetti, S. Establishment and characterization of four human epithelial ovarian carcinoma cell lines. Cancer, 74, 900-906 (1994).
4. Wilson, A. P., Dent, M., Pejovic, T., Hubbold, L. and Radford, H. Characterisation of seven human ovarian tumour cell lines. Br. J. Cancer, 74, 722-727 (1996).
5. Yanagibashi, T., Gorai, I., Nakazawa, T., Miyagi, E., Hirahara, F., Kitamura, H. and Minaguchi, H. Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br. J. Cancer, 76, 829-835 (1997).
6. Wong, W. S., Wong, Y. F., Ng, Y. T., Huang, P. D., Chew, E. C., Ho, T. H. and Chang, M. Z. Establishment and characterization of a new human cell line derived from ovarian clear cell carcinoma. Gynecol. Oncol., 38, 37-45 (1990).
7. Gorai, I., Nakazawa, T., Miyagi, E., Hirahara, F., Nagashima, Y. and Minaguchi, H. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol. Oncol., 57, 33-46 (1995).
8. Hainaut, P. and Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res., 77, 81-137 (2000).
9. Appella, E. and Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem., 268, 2764-2772 (2001).
10. Moll, U. M., Riou, G. and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89, 7262-7266 (1992).
11. Benninghoff, J., Kartarius, S., Teleb, Z., Selter, H., Unteregger, G., Zwergel, T., Wullich, B. and Montenarh, M. Two different forms of p53 localized differently within cells of urogenital tumours. Cancer Lett., 144, 55-64 (1999).
12. Vogelstein, B., Lane, D. and Levine, A. J. Surfing the p53 network. Nature, 408, 307-310 (2000).
13. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B. and Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55, 678-684 (1993).
14. Runnebaum, I. B., Tong, X. W., Möbus, V. J., Kieback, D. G., Rosenthal, H. E. and Kreienberg, R. p53 mutant His 175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6. FEBS Lett., 353, 29-32 (1994).
15. Fajac, A., Da Silva, J., Ahomadegbe, J. C., Rateau, J. G., Bernaudin, J. F., Riou, G. and Benard, J. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int. J. Cancer, 68, 67-74 (1996).
16. Becker, J. L., Papenhausen, P. R. and Widen, R. H. Cytogenetic, morphologic and oncogene analysis of a cell line derived from a heterologous mixed mullerian tumor of the ovary. In Vitro Cell. Dev. Biol. Anim., 33, 325-331 (1997).
17. Dolo, V., Ginestra, A., Violini, S., Miotti, S., Festuccia, C., Miceli, D., Migliavacca, M., Rinaudo, C., Romano, F. M., Brisdelli, F., Canevari, S., Pavan, A. and Vittorelli, M. L. Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line. Oncol. Res., 9, 129-138 (1997).
18. Baas, I. O., Hruban, R. H. and Offerhaus, G. J. Clinical applications of detecting dysfunctional p53 tumor suppressor protein. Histol. Histopathol., 14, 279-284 (1999).
19. Bar, J. K. and Harlozińska, A. Morphological and phenotypic characterization of a new established ovarian carcinoma cell line (OvBH-1). Anticancer Res., 20, 2975-2980 (2000).
20. Michalovitz, D., Halevy, O. and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62, 671-680 (1990).
21. Zhang, W., Guo, X. Y., Hu, G. Y., Liu, W. B., Shay, J. W. and Deisseroth, A. B. A temperature-sensitive mutant of human p53. EMBO J., 13, 2535-2544 (1994).
22. Yamato, K., Yamamoto, M., Hirano, Y. and Tsuchida, N. A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes. Oncogene, 11, 1-6 (1995).
23. Ponchel, F. and Milner, J. Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo. Br. J. Cancer, 77, 1555-1561 (1998).
24. Freedman, D. A., Wu, L. and Levine, A. J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci., 55, 96-107 (1999).
25. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. WAFI, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
26. Engel, L. W. and Young, N. A. Human breast carcinoma cells in continuous culture: a review. Cancer Res., 38, 4327-4339 (1978).
27. Fogh, J., Fogh, J. M. and Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst., 59, 221-226 (1977).
28. Srivenugopal, K. S., Shou, J., Mullapudi, S. R., Lang, F. F., Jr., Rao, J. S. and Ali-Osman, F. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin. Cancer Res., 7, 1398-1409 (2001).
29. Sambrook, J., Fritsch, E. E. and Maniatis, T. "Molecular Cloning: A Laboratory Manual" (1989). Cold Spring Harbor Laboratory Press, New York.
30. Ormerod, M. G. and Kubbies, M. Cell cycle analysis of asynchronous cell populations by flow cytometry using bromodeoxyuridine label and Hoechst-propidium iodide stain. Cytometry, 13, 678-685 (1992).
31. Craig, A. L., Burch, L., Vojtesek, B., Mikutowska, J., Thompson, A. and Hupp, T. R. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J., 342, 133-141 (1999).
32. Stephen, C. W., Helminen, P. and Lane, D. P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J. Mol. Biol., 248, 58-78 (1995).
33. Vojtesek, B., Bartek, J., Midgley, C. A. and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151, 237-244 (1992).
34. Harlow, E., Crawford, L. V., Pim, D. C. and Williamson, N. M. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol., 39, 861-869 (1981).
35. Legros, Y., Meyer, A., Ory, K. and Soussi, T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene, 9, 3689-3694 (1994).
36. Ball, R. K., Siegl, B., Quellhorst, S., Brandner, G. and Braun, D. G. Monoclonal antibodies against simian virus 40 nuclear large T tumour antigen: epitope mapping, papova virus cross-reaction and cell surface staining. EMBO J., 3, 1485 -1491 (1984).
37. Milner, J., Cook, A. and Sheldon, M. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene, 1, 453-455 (1987).
38. Cho, Y., Gorina, S., Jeffrey, P. D. and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346-355 (1994).
39. Bar, J. K. and Harlozińska, A. Clinical utility of 53 and cerbB-2 immunohistostaining in the diagnosis of tumor effusions. Diagn. Oncol., 95, 224-229 (1995).
40. Oren, M., Bienz, B., Givol, D., Rechavi, G. and Zakut, R. Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen. EMBO J., 2, 1633-1639 (1983).
41. Zaffaroni, N., Silvestrini, R., Orlandi, L., Bearzatto, A., Gornati, D. and Villa, R. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br. J. Cancer, 77, 1378-1385 (1998).
42. Judson, P. L., Watson, J. M., Gehrig, P. A., Fowler, W. C., Jr. and Haskill, J. S. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res., 59, 2425-2432 (1999).
43. O'Neill, C. F., Koberle, B., Masters, J. R. and Kelland, L. R. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br. J. Cancer, 81, 1294-1303 (1999).
44. cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene, 18, 4808-4818 (1999).
45. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704 (1993).
46. Kern, S. E. p53: tumor suppression through control of the cell cycle. Gastroenterology, 106, 1708-1711 (1994).
47. Ando, T., Kawabe, T., Ohara, H., Ducommun, B., Itoh, M. and Okamoto, T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J. Biol. Chem., 276, 42971-42977 (2001).
48. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-299 (1997).
49. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature, 387, 299-303 (1997).
50. Chehab, N. H., Malikzay, A., Stavridi, E. S. and Halazonetis, T. D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. USA, 96, 13777-13782 (1999).
51. Unger, T., Juven-Gershon, T., Moallem, E., Berger, M., Vogt Sionov, R., Lozano, G., Oren, M. and Haupt, Y. Critical role for Ser2O of human p53 in the negative regulation of p53 by Mdm2. EMBO J., 18, 1805-1814 (1999).
52. Akakura, S., Yoshida, M., Yoneda, Y. and Horinouchi, S. A role for Hsc70 in regulating nucleocytoplasmic transport of a temperature-sensitive p53 (p53Val-135). J. Biol. Chem., 276, 14649-14657 (2001).
53. Middeler, G., Zerf, K., Jenovai, S., Thulig, A., Tschodrich-Rotter, M., Kubitscheck, U. and Peters, R. The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene, 14, 1407-1417 (1997).
54. Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J. and Wahl, G. M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J., 18, 1660-1672 (1999).
55. Hupp, T. R., Meek, D. W., Midgley, C. A. and Lane, D. P. Regulation of the specific DNA binding function of p53. Cell, 71, 875-886 (1992).
56. Hupp, T. R. and Lane, D. P. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem., 270, 18165-18174 (1995).
57. Hupp, T. R. and Lane, D. P. Allosteric activation of latent p53 tetramers. Curr. Biol., 4, 865-875 (1994).
58. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W. and Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 12, 2831-2841 (1998).
59. Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D. and Berger, S. L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol., 19, 1202-1209 (1999).
60. Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P. and Pelicci, P. G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature, 406, 207-210 (2000).
61. Kobet, E., Zeng, X., Zhu, Y., Keller, D. and Lu, H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA, 97, 12547-12552 (2000).
62. Ito, A., Lai, C. H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E. and Yao, T. P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J., 20, 1331-1340 (2001).
63. Waterman, M. J., Stavridi, E. S., Waterman, J. L. and Halazonetis, T. D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet., 19, 175-178 (1998).
64. Milner, J. and Medcalf, E. A. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. J. Mol. Biol., 216, 481-484 (1990).
65. Milner J. Forms and functions of p53. Semin. Cancer Biol., 5, 211-219 (1994).